125 related articles for article (PubMed ID: 17687160)
1. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.
Saylor PJ; Reid TR
J Clin Oncol; 2007 Aug; 25(23):3544-6. PubMed ID: 17687160
[No Abstract] [Full Text] [Related]
2. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK
Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor.
Mutlu H; Büyükçelik A; Akça Z; Kaya N
J Oncol Pharm Pract; 2014 Aug; 20(4):298-301. PubMed ID: 23929730
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib and Thrombosis.
Lamba G; Deol R; Shah D; Sahni R; Malhotra BK
J Gastrointest Cancer; 2012 Sep; 43 Suppl 1():S128-30. PubMed ID: 21881834
[No Abstract] [Full Text] [Related]
5. Guillain-Barré syndrome after treatment with sunitinib malate?
Mulherin B; Loconte NK; Holen KD
Oncology (Williston Park); 2008 Jan; 22(1):66-7, 70-1. PubMed ID: 18251284
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.
Michels J; Lassau N; Gross-Goupil M; Massard C; Mejean A; Escudier B
Invest New Drugs; 2010 Oct; 28(5):690-3. PubMed ID: 19547920
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience.
Kefeli U; Buyuberber S; Akyol M; Yildiz R; Kaplan MA; Ciltas A; Sevinc A; Karaca H; Seker M; Ozdemir N; Alacacioglu A; Coskun U; Isikdogan A; Dane F; Gumus M; Ozkan M; Suner A; Tarhan MO; Benekli M
Hepatogastroenterology; 2013 Jun; 60(124):647-52. PubMed ID: 23165189
[TBL] [Abstract][Full Text] [Related]
8. [Drug Interaction between Sutent (sunitinib) and Bi-spirogyl (spiramycin-metronidazol): risk of toxicity].
Trabelsi S; Boussen H; Gaïes E; Salouage I; El Aïdli S; Daghfous R; Loueslati MH; Lakhal M; Belkahia C
Therapie; 2008; 63(6):475-6. PubMed ID: 19374036
[No Abstract] [Full Text] [Related]
9. Acute severe hypothyroidism induced by sunitinib.
Prat A; Serrano C; Valverde C; Calvo E
Radiother Oncol; 2008 Oct; 89(1):124-5. PubMed ID: 18502526
[No Abstract] [Full Text] [Related]
10. [Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors].
Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):801-806. PubMed ID: 31550816
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
12. Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.
Ann Intern Med; 2006 Nov; 145(9):I44. PubMed ID: 17088575
[No Abstract] [Full Text] [Related]
13. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib?
ten Freyhaus K; Homey B; Bieber T; Wilsmann-Theis D
Br J Dermatol; 2008 Jul; 159(1):242-3. PubMed ID: 18489600
[No Abstract] [Full Text] [Related]
14. Ripretinib (Qinlock) for GIST.
Med Lett Drugs Ther; 2021 Apr; 63(1621):e56-e57. PubMed ID: 33830971
[No Abstract] [Full Text] [Related]
15. Transient sunitinib resistance in gastrointestinal stromal tumors.
Bracci R; Maccaroni E; Cascinu S
N Engl J Med; 2013 May; 368(21):2042-3. PubMed ID: 23697529
[No Abstract] [Full Text] [Related]
16. [Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib].
Rodríguez-Reimúndes E; Perazzo F; Vilches AR
Medicina (B Aires); 2011; 71(2):158-60. PubMed ID: 21550933
[TBL] [Abstract][Full Text] [Related]
17. Transient sunitinib-induced coma in a patient with fibromyxoid sarcoma.
Arnaud L; Schartz NE; Bousquet G; Sarandi F; Verola O; Madelaine I; Kerob D; Lebbe C
J Clin Oncol; 2008 Mar; 26(9):1569-71. PubMed ID: 18349416
[No Abstract] [Full Text] [Related]
18. Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature.
Gallucci G; Tartarone A; Tocchetti CG; Bochicchio AM; Coccaro M; Capobianco A; Maurea N; Improta G; Zupa A; Aieta M
Future Oncol; 2013 Jan; 9(1):127-33. PubMed ID: 23252570
[TBL] [Abstract][Full Text] [Related]
19. Cardiotoxicity associated with sunitinib.
Hariharan S; Lowry S
Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
[No Abstract] [Full Text] [Related]
20. Management of complicated tumor response to tyrosine-kinase inhibitors in gastrointestinal stromal tumors.
Tirotta F; Fumagalli E; Colombo C; Morosi C; Barisella M; Radaelli S; Frezza AM; Casali PG; Gronchi A; Fiore M
J Surg Oncol; 2019 Aug; 120(2):256-261. PubMed ID: 31066052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
